13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04660539
(ClinicalTrials.gov)
January 11, 202124/11/2020A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)Neuromyelitis Optica Spectrum DisorderDrug: satralizumab;Drug: azathioprine (AZA);Drug: mycophenolate mofetil (MMF);Drug: oral corticosteroidsHoffmann-La RocheNULLNot yet recruiting18 YearsN/AAll127Phase 3United States;Bulgaria;Canada;Croatia;Germany;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Poland;Puerto Rico;Romania;Spain;Taiwan;Turkey;Ukraine;United Kingdom
2ChiCTR1900025744
2019-09-012019-09-07Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trialClinical effectiveness and safety Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial neuromyelitis optica spectrum disorder (NMOSD)1:Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg);2:Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750~3000mg/day);The Ophthalmology Department of the Chinese Peoples Liberation Army HospitalNULLRecruiting1870Both1:30;2:30;Phase 4China
3JPRN-jRCTs051180080
12/12/201827/02/2019Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese PatientsTreatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients - An open treatment trial of NMO with MMF Neuromyelitis opticaMycophenolate mofetil treatment for 1 yearSekiguchi KenjiNULLRecruiting>= 20age old< 80age oldBoth10Phase 2Japan
4JPRN-UMIN000031135
2018/04/0101/04/2018Treatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese PatientsTreatment of Neuromyelitis Optica with Mycophenolate Mofetil in Japanese Patients - An open treatment trial of NMO with MMF Neuromyelitis OpticaMycophenolate mofetil treatment for 1 yearKobe University HospitalNULLRecruiting20years-old80years-oldMale and Female10Not selectedJapan
5ChiCTR-OPB-16007730
2016-01-012016-01-09Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA)Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA) Neuromyelitis opticaCase series:Mycophenolate Mofetil;The third affiliated hospital,Sun Yat-sen universityNULLRecruiting1865BothCase series:100;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02809079
(ClinicalTrials.gov)
January 201612/6/2016Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese PatientsMycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese PatientsNeuromyelitis Optica Spectrum Disorders;Mycophenolate Mofetil;Efficacy and SafetyDrug: Mycophenolate mofetil;Drug: PrednisoneThird Affiliated Hospital, Sun Yat-Sen UniversityZhongshan Ophthalmic Centre, Sun Yat-sen University;Nangfang Hospital, Southern Medical UniversityEnrolling by invitation18 Years65 YearsBoth100Phase 4NULL
7ChiCTR-ICR-15007177
2014-08-302014-05-30A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic NeuritisA Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis Neuromyelitis Optica associated Optic Neuritis1:Intravenous 100mg Rituximab, 1/week*4 ;2:Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day);The Ophthalmology Department of the Chinese Peoples Liberation Army HospitalNULLRecruiting1870Both1:30;2:30;China
8NCT00618527
(ClinicalTrials.gov)
August 20066/2/2008Combination Therapy Using Cellcept and Rebif in RRMSCombination Therapy Using Mycophenolate Mofetil (CellCept) and Human Interferon beta1a (Rebif) in Early Treatment of Multiple SclerosisMultiple SclerosisDrug: mycophenolate mofetil (Cellcept);Drug: human interferon beta 1a (Rebif)Aaron BosterEMD Serono;PfizerCompleted18 Years65 YearsBoth31Phase 0United States
9NCT00324506
(ClinicalTrials.gov)
May 20069/5/2006Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple SclerosisA Randomized, Open-label, Parallel-Group Multicenter Study to Determine the Safety/Efficacy of Mycophenolate Mofetil in Mono & Combination Therapy With Interferon Beta 1a in Patients With Relapsing Remitting Multiple SclerosisMultiple SclerosisDrug: Mycophenolate Mofetil (CellCept)University of Texas Southwestern Medical CenterAspreva PharmaceuticalsCompleted18 Years55 YearsBoth43Phase 2United States
10NCT00223301
(ClinicalTrials.gov)
July 200419/9/2005Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple SclerosisA One-Year Prospective, Randomized, Placebo-Controlled, Double-Blind, Phase II/III Safety Trial of Combination Therapy With IFN Beta-1a (Avonex) and Mycophenolate Mofetil (Cellcept) in Early Multiple SclerosisMultiple SclerosisDrug: Mycophenolate Mofetil (cellcept)University of Texas Southwestern Medical CenterRoche Pharma AG;Biogen IdecCompleted21 Years45 YearsBoth24Phase 2;Phase 3United States